share_log

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $9

Benzinga ·  Aug 2, 2023 04:11

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $10 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment